Intuitive Surgical (ISRG)
NASDAQ: ISRG · Medical Instruments · Sunnyvale, CA
Our rating: Positive
Positive reaffirmed at $443.85, moderate conviction, October 22, 2026.
Breaks if: The Positive view would break if year-over-year revenue growth falls below 12% — roughly half the current 20.5% rate — for two consecutive quarters within the next twelve months, signaling the franchise is decelerating faster than the 56x multiple can absorb. A sustained decline in net margin below 22% for two straight quarters would likewise prompt a downgrade, indicating operating leverage is reversing rather than building. Either condition confirmed in back-to-back quarters would shift the call toward Cautious.
Key figures
| Market value | $138.3B |
|---|---|
| Revenue, last 12 months | $11.6B |
| Net income, last 12 months | $3.0B |
| Free cash flow, last 12 months | $3.6B |
| Price to earnings | 46.8× |
| Free cash flow yield | 2.6% |
| Dividend yield | 0.0% |
| Operating margin | 28.4% |
| Return on equity | 18.0% |
| Beta to the S&P 500 | 1.08 |
| Volatility, annualized | 34.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $3.0B | 21.7% | $1.49 | $1.1B |
| June 30, 2026 | $2.9B | 18.5% | $2.29 | $948M |
| March 31, 2026 | $2.8B | 23.0% | $2.28 | $809M |
| December 31, 2025 | $2.9B | 18.8% | $2.20 | $730M |
| September 30, 2025 | $2.5B | 22.9% | $1.95 | $736M |
| June 30, 2025 | $2.4B | 21.4% | $1.81 | $560M |
| March 31, 2025 | $2.3B | 19.2% | $1.92 | $465M |
| December 31, 2024 | $2.4B | 25.2% | $1.89 | $511M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $3.45B: Claude 72%, Gemini 88%, Mistral 72%
- Diluted earnings per share are at least $2.20: Claude 62%, Gemini 40%, Mistral 58%
- Free cash flow for the quarter is at least $0.73B: Claude 88%, Gemini 95%, Mistral 90%
21 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.